Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Article in Chinese | WPRIM | ID: wpr-333617

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the effects of triptolide on Notch receptor and ligand expressions in rats with adjuvant-induced arthritis (AA).</p><p><b>METHODS</b>Forty rats were randomly divided into normal control (NC) group, model (MC) group, methotrexate group and triptolide groups. Rat models of AA were established by an intradermal injection of 0.1 mL Freund's complete adjuvant into the right paw. Twelve days after the injection, the rats were treated with corresponding drugs for 30 days; the rats in NC group and MC group were given saline only. Paw edema volume (E), arthritis index (AI), pulmonary function, histomorphologies, and Notch receptor/ ligand expression in the lung tissue were analyzed after the treatments.</p><p><b>RESULTS</b>Compared with the NC group, E, AI, Notch3, Notch4, and Delta1 expressions in the lung tissues significantly increased while pulmonary function and pulmonary expressions of Notch1, Jagged1, and Jagged2 significantly decreased the model rats (P<0.01). Compared with the MC group, triptolide-treated rats showed significantly improved pulmonary functions, increased expressions of Notch1, Jagged1, and Jagged2 and decreased expressions of Notch3, Notch4, and Delta1 in the lungs (P<0.05, P<0.01); the therapeutic effect of triptolide was better than that of methotrexate.</p><p><b>CONCLUSION</b>Triptolide can reduce inflammatory reaction and immune complex deposition to improve joint and pulmonary symptoms in rats with AA possibly by up-regulating the expressions of Notch3, Notch4, and Delta1 and down-regulating the expressions of Jagged1, Jagged2, and Notch1.</p>


Subject(s)
Animals , Arthritis, Experimental , Drug Therapy , Metabolism , Calcium-Binding Proteins , Metabolism , Diterpenes , Pharmacology , Down-Regulation , Drugs, Chinese Herbal , Epoxy Compounds , Pharmacology , Intercellular Signaling Peptides and Proteins , Metabolism , Intracellular Signaling Peptides and Proteins , Metabolism , Jagged-1 Protein , Jagged-2 Protein , Ligands , Lung , Metabolism , Membrane Proteins , Metabolism , Methotrexate , Pharmacology , Phenanthrenes , Pharmacology , Rats , Receptor, Notch3 , Receptor, Notch4 , Receptors, Notch , Metabolism , Respiratory Insufficiency , Drug Therapy , Serrate-Jagged Proteins
2.
Journal of Integrative Medicine ; (12): 428-434, 2013.
Article in English | WPRIM | ID: wpr-308224

ABSTRACT

<p><b>BACKGROUND</b>Rheumatoid arthritis (RA), as a common systemic inflammatory autoimmune disease, affects approximately 1 in 100 individuals. Effective treatment for RA is not yet available because current research does not have a clear understanding of the etiology and pathogenesis of RA. Xinfeng Capsule, a patent Chinese herbal medicine, has been used in the treatment of RA in recent years. Despite its reported clinical efficacy, there are no large-sample, multicenter, randomized trials that support the use of Xinfeng Capsule for RA. Therefore, we designed a randomized, double-blind, multicenter, placebo-controlled trial to assess the efficacy and safety of Xinfeng Capsule in the treatment of RA.</p><p><b>METHODS AND DESIGN</b>This is a 12-week, randomized, placebo-controlled, double-blind, multicenter trial on the treatment of RA. The participants will be randomly assigned to the experimental group and the control group at a ratio of 1:1. Participants in the experimental group will receive Xinfeng Capsule and a pharmaceutical placebo (imitation leflunomide). The control group will receive leflunomide and an herbal placebo (imitation Xinfeng Capsule). The American College of Rheumatology (ACR) Criteria for RA will be used to measure the efficacy of the Xinfeng Capsule. The primary outcome measure will be the percentage of study participants who achieve an ACR 20% response rate (ACR20), which will be measured every 4 weeks after randomization. Secondary outcomes will include the ACR50 and ACR70 responses, the side effects of the medications, the Disease Activity Score 28, RA biomarkers, quality of life, and X-rays of the hands and wrists. The first four of the secondary outcomes will be measured every 4 weeks and the others will be measured at baseline and after 12 weeks of treatment.</p><p><b>DISCUSSION</b>The result of this trial will help to evaluate whether Xinfeng Capsule is effective and safe in the treatment of RA.</p><p><b>TRIAL REGISTRATION</b>This trial has been registered in ClinicalTrials.gov. The identifier is NCT01774877.</p>


Subject(s)
Adolescent , Adult , Aged , Arthritis, Rheumatoid , Drug Therapy , Capsules , Clinical Protocols , Double-Blind Method , Drugs, Chinese Herbal , Therapeutic Uses , Humans , Middle Aged , Quality Control , Sample Size
3.
Chinese Journal of Hepatology ; (12): 896-899, 2009.
Article in Chinese | WPRIM | ID: wpr-247632

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the seroprevalence of anti-HAV IgG in adults of 4 cities in China.</p><p><b>METHODS</b>Serum samples were collected from 2390 local residents aged between 20 to 88 years from Beijing, Shanghai, Wuhan and Guangzhou. The anti-HAV IgG in sera was detected with a microparticle enzyme immunoassay (MEIA).</p><p><b>RESULTS</b>The anti-HAV IgG seroprevalence in female of 30 to 39 years in Beijing (64.58%, 62/96) was higher than that in male (45.57% 36/79)) (x(2) = 6.358, P = 0.012). It increased with age in adults of Beijing and Guangzhou. The rates were 54.22 % (90/166), 56.00% (98/175) and 67.18% (88/131) for the 20-, 30- and 40-49 age groups in Beijing (x(2) = 4.76, P = 0.03); and 52.83% (56/106), 52.50% (63/120), 82.46% (94/114), 89.80% (88/98) and 96.77% (60/62) for the 20-, 30-, 40-, 50- and 60-88 age groups in Guangzhou, respectively (x(2) = 72.58, P less than 0.01). This trend was not found in Shanghai and Wuhan (x2 = 0.96, 2.99; P = 0.33, 0.08 respectively). The seroprevalence rates of anti-HAV IgG in the 20 to 39 age group of Beijing, Shanghai, Guangzhou and Wuhan were 55.13% (188/341), 63.93% (429/671), 52.65% (119/226) and 78.37% (308/393), respectively.</p><p><b>CONCLUSION</b>The seroprevalence rates of anti-HAV IgG in young adults aged 20 to 39 years of the four cities are relatively low, and HAV vaccination should be suggested for the susceptible population of this age group in China.</p>


Subject(s)
Adult , Age Distribution , Aged , Aged, 80 and over , China , Epidemiology , Female , Hepatitis A , Epidemiology , Allergy and Immunology , Hepatitis A Antibodies , Blood , Hepatitis A Virus, Human , Allergy and Immunology , Humans , Immunoglobulin G , Blood , Male , Middle Aged , Seroepidemiologic Studies , Sex Distribution , Urban Population , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL